https://www.selleckchem.com/products/U0126.html
Background Accumulating evidence proposed JAK inhibitors as therapeutic targets warranting rapid investigation. Objective This study evaluated the efficacy and safety of ruxolitinib, a Janus-associated kinase (JAK1/2) inhibitor, for COVID-19. Methods We conducted a prospective, multicenter, single-blind, randomized controlled phase II trial involving patients with severe COVID-19. Results Forty-three patients were randomly assigned (11) to receive ruxolitinib plus SoC treatment (22 patients) or placebo based on SoC treatment (21 patients)
Like
Comment
Share
